Advertorial

Pfizer Director of Biostatistics explores adaptive dose-finding designs in oncology early phase trials

Posted: 22 February 2017 | | No comments yet

Pfizer Director of Biostatistics to deliver key presentation at the 9th Adaptive Designs in Clinical Trials conference in London in April…

ADAPTIVE-DESIGNS

SMi has confirmed that Bo Huang, Director of Biostatistics at Pfizer has joined the expert speaker lineup for the 9th Adaptive Designs in Clinical Trials event on the 3rd & 4th of April 2017 in London.

Bo is an avid advocate of adaptive innovative designs and designed the first Bayesian model-based clinical trial at Pfizer Oncology. Following his successful presentation last year, Bo returns this year to present a keynote on Adaptive Dose Finding Designs in Oncology Early Phase Trials. Through this exclusive presentation, Bo will discuss the time-to-event reassessment method with adaptive weight function incorporating cyclical data. He will also highlight practical implications of adaptive design on Pfizer oncology drug development with two case studies.

In a quickfire interview with SMi Group, Bo commented on the future of adaptive clinical trials.

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

“I envision more applications of adaptive designs in clinical trials, especially in the pharmaceutical industry. As we enter the era of precision medicine, more statistically efficient designs are appealing to clinical practitioners as a means to lower the ever-increasing cost and shorten the time to reach the market and patients,” he said.

The full interview can be downloaded from the event website.

Bo joins a speaker lineup of industry-leading innovators from AstraZeneca, Pfizer, Sanofi, Boehringer-Ingelheim, Grünenthal, Amgen, Novartis, Blueberry Therapeutics, and more.

Now nearly running for a decade, Adaptive Designs in Clinical Trials will feature key presentations that will discuss and deliberate key topics such as new approaches in adaptive designs, clinical strategies, optimising drug development in key therapy areas and industry-led approaches to clinical trial success. A detailed agenda is available to view on the event website.

The event will also feature a post-conference workshop on writing clinical trial simulators hosted by Berry Consultants.

For more details about the conference and to register, visit.

9th annual ADAPTIVE DESIGNS IN CLINICAL TRIALS 3rd & 4th APRIL 2017 Copthorne Tara Hotel, Kensington, London, UK

Contact Information:

For sponsorship and exhibition queries please contact Alia Malick at [email protected]
For delegate queries please contact Fateja Begum at [email protected]
For media queries please contact Honey de Gracia at [email protected]

Related topics

Related organisations

Related people

Leave a Reply

Your email address will not be published. Required fields are marked *